Milan Sheth, MD
Internal Medicine · Lenoir City, TNNPI 1083694707
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $51,940 of the $57,718 with a category attached, or 90.0%. Novartis accounts for 92.5% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2019 at $47,975 and has fallen 97.9% since, to $1,021 in 2025. Among internal medicine clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 269 payments — averaging $214.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$53K
- Novo Nordisk$769
- Pfizer$404
- AstraZeneca$372
- AbbVie$278
- Dexcom, Inc.$247
- plus $2K from 24 others
What the payments were for
- Speaking & faculty fees$51,94090%
- Travel & lodging$5151%
- Food & beverage$5,1629%
- Education$1020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 65 | $53,398 |
| Novo Nordisk | 50 | $769 |
| Pfizer | 14 | $404 |
| AstraZeneca | 17 | $372 |
| AbbVie | 17 | $278 |
| Dexcom, Inc. | 11 | $247 |
| Bayer | 9 | $246 |
| Amgen | 16 | $213 |
| Otsuka America Pharmaceutical, Inc. | 8 | $204 |
| Lilly USA, LLC | 10 | $195 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $158 |
| GSK | 5 | $151 |
| Astellas Pharma US Inc | 4 | $150 |
| Abbott | 6 | $130 |
| E.r. Squibb & Sons, L.L.C. | 5 | $123 |
| Sumitomo Pharma America, Inc. | 7 | $122 |
| Boston Scientific | 2 | $104 |
| Merck | 2 | $92 |
| Boehringer Ingelheim | 3 | $88 |
| Xeris Pharmaceuticals, Inc. | 3 | $58 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| Amarin Pharma, Inc. | 2 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| W. L. Gore & Associates, Inc. | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Lantheus Medical Imaging, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$57,718 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 212 | $168,035 |
| OzempicSemaglutide | 99 | $124,155 |
| JardianceEmpagliflozin | 66 | $76,364 |
| XareltoRivaroxaban | 82 | $76,262 |
| MounjaroTirzepatide | 32 | $50,821 |
| EntrestoSacubitril/Valsartan | 45 | $46,068 |
| MyrbetriqMirabegron | 39 | $35,648 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $32,565 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 35 | $31,410 |
| VraylarCariprazine Hcl | 21 | $30,774 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $28,266 |
| TradjentaLinagliptin | 24 | $26,636 |
| LinzessLinaclotide | 33 | $24,060 |
| JanumetSitagliptin Phos/Metformin Hcl | 24 | $23,577 |
| TrulicityDulaglutide | 20 | $22,872 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $404 | $176,186234 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta, Glyxambi, Spiriva Respimat | $88 | $165,652157 claims |
| Novo NordiskOzempic | $769 | $124,15599 claims |
| Lilly USA, LLCMounjaro, Trulicity | $195 | $73,69352 claims |
| AbbVieVraylar, Linzess | $278 | $54,83554 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $151 | $50,79282 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $372 | $48,08256 claims |
| NovartisEntresto | $53,398 | $46,06845 claims |
| Astellas Pharma US IncMyrbetriq | $150 | $35,64839 claims |
| MerckJanumet, Januvia | $92 | $33,99239 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Lenoir City
- John AndersonNashville$1.5M
- Tracie WalkerJackson$488K
- Nathan TrenthamEtowah$404K
- Dennis DeruelleKnoxville$263K
- Devin ShermanFranklin$191K
- Lewis HagoodKnoxville$143K
- Temidayo AbeNashville$113K
- Kenya KozawaSweetwater$86K
- Wayne RileyNashville$86K
- Maighan SeagroveChattanooga$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.